Taysha Gene Therapies (TSHA) Stock: Buy, Sell, or Hold?
TSHA - Taysha Gene Therapies, Inc. Common Stock
$5.02
-0.14 (-2.71%)
▼
5d:
-9.87%
30d:
-21.62%
90d:
-10.04%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 03, 2026
Get Alerted When TSHA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TSHA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TSHA shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: TSHA is currently trading at $5.02, which is considered oversold relative to its 30-day fair value range of $5.55 to $6.37.
Technical Outlook: Technically, TSHA is in a uptrend. The price is currently testing key support at $4.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TSHA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.33 (+165.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TSHA is in a uptrend. The price is currently testing key support at $4.98. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TSHA scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.33 (+165.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.55 -
$6.37
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 165.6% below Wall St target ($13.33)
- WARNING: Composite score 45/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$5.55 -
$6.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$4.98
Resistance Level
$5.96
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-10.85
Wall Street Target
$13.33
(+165.6%)
Revenue Growth (YoY)
171.3%
Share & Embed Analysis
Last updated: September 12, 2026 10:15 AM ET
Data refreshes hourly during market hours. Next update: 11:15 AM
Data refreshes hourly during market hours. Next update: 11:15 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TSHA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Sukumar Nagendran
SELL
200000 shares
2026-04-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 50 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$289 | 59 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 41 HOLD |
